Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...

Novo Nordisk NVO and Structure Therapeutics GPCR have emerged as noteworthy companies in the obesity space. A market leader ...

Background/Aims The neuroprotective effect of nicotinamide (NAM) supplementation has been demonstrated in both animal models ...

Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDTCompany ...

The Hyperhidrosis Treatment Market is witnessing significant momentum due to increasing awareness about excessive sweating disorders, rising adoption of minimally invasive treatments, and advancements ...

For decades, stroke patients with swallowing difficulties have routinely received crushed tablets to reduce the risk of ...

Rosuvastatin oral tablet is a prescription medication that is used to treat high cholesterol and reduce the risk of heart disease. More common side effects of rosuvastatin include headache, muscle ...

Novo Nordisk has fallen behind its archrival, Eli Lilly, in the obesity drug market. Compounded GLP-1 drugs have become such an issue that Novo Nordisk changed its CEO. Expectations are so low that ...

AUSTIN, Texas and TOKYO, Oct. 13, 2025 /PRNewswire/ -- The cardiovascular drugs market was valued at US$ 174.6 billion in 2024 and is projected to reach US$ 247.8 billion by 2033, achieving a CAGR of ...

Oxybutynin immediate-release oral tablet is used to treat overactive bladder. This form of oxybutynin is available in a generic version only. More common side effects of oxybutynin include being ...

My Instagram feed is very curated, so I rarely see things I don’t want to. Even though I’m a fat 43-year old single woman, I don’t see weight loss, work out, or dating ads. So it took a while for the ...

Data reveal how the global challenge to reduce deaths and infections from drug-resistant bacteria is not going according to plan. “Antimicrobial resistance is escalating, but the pipeline of new ...